{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:21:08Z","timestamp":1768828868298,"version":"3.49.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.trre.2024.100873","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T22:58:40Z","timestamp":1724367520000},"page":"100873","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature"],"prefix":"10.1016","volume":"38","author":[{"given":"Silvia","family":"Corcione","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tommaso","family":"Lupia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Vita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Sidoti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Zanotto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Solidoro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Biancone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Costa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Balagna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Giuseppe","family":"De Rosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2024.100873_bb0005","doi-asserted-by":"crossref","DOI":"10.1097\/MOT.0000000000001139","article-title":"Recent advances in cytomegalovirus infection management in solid organ transplant recipients","author":"Grossi","year":"2024","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2024.100873_bb0010","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical Trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2024.100873_bb0015","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000004855","article-title":"What\u2019s new: updates on cytomegalovirus in solid organ transplantation","author":"Stewart","year":"2023","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100873_bb0020","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cmi.2023.03.020","article-title":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","volume":"29","author":"Razonable","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2024.100873_bb0025","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the Management of Cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100873_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Intern: Off J Eur Soc Organ Transplant"},{"key":"10.1016\/j.trre.2024.100873_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104711","article-title":"Advances in the genotypic diagnosis of cytomegalovirus antiviral drug resistance","volume":"176","author":"Chou","year":"2020","journal-title":"Antivir Res"},{"key":"10.1016\/j.trre.2024.100873_bb0040","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1093\/cid\/ciab988","article-title":"Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial","volume":"75","author":"Avery","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100873_bb0055","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s41073-019-0064-8","article-title":"SANRA-a scale for the quality assessment of narrative review articles","volume":"4","author":"Baethge","year":"2019","journal-title":"Res Integrity Peer Rev"},{"key":"10.1016\/j.trre.2024.100873_bb0060","doi-asserted-by":"crossref","DOI":"10.3389\/ti.2024.11985","article-title":"A novel case of CMV resistance to Valganciclovir and Maribavir in a renal transplant patient","volume":"37","author":"Pearce","year":"2024","journal-title":"Transpl Intern: Off J Eur Soc Organ Transplant"},{"key":"10.1016\/j.trre.2024.100873_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14929","article-title":"Real world experience with Maribavir for the treatment of cytomegalovirus in solid organ transplant recipients","volume":"37","author":"Sabatino","year":"2023","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100873_bb0070","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13869","article-title":"Maribavir does not significantly influence tacrolimus dose requirements in solid organ transplant recipients","volume":"24","author":"Sabatino","year":"2022","journal-title":"Transpl Infect Disease: Off J Transplant Soc"},{"key":"10.1016\/j.trre.2024.100873_bb0075","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14017","article-title":"Maribavir use in patients with renal impairment","volume":"25","author":"Koff","year":"2023","journal-title":"Transpl Infect Disease: Off J Transplant Soc"},{"key":"10.1016\/j.trre.2024.100873_bb0080","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/TP.0000000000000275","article-title":"Suspicion of interaction between maribavir and everolimus in a renal transplant recipient","volume":"98","author":"Verdier","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100873_bb0085","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1016\/j.transproceed.2013.01.082","article-title":"Maribavir use in practice for cytomegalovirus infection in French transplantation centers","volume":"45","author":"Alain","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2024.100873_bb0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1399-0012.2007.00761.x","article-title":"Emergence of drug-resistant cytomegalovirus in the era of valganciclovir prophylaxis: therapeutic implications and outcomes","volume":"22","author":"Eid","year":"2008","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2024.100873_bb0095","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13960","article-title":"Female sex and advanced age are associated with invasive cytomegalovirus disease in solid organ transplant recipients","volume":"24","author":"Perry","year":"2022","journal-title":"Transpl Infect Disease: Off J Transplant Soc"},{"key":"10.1016\/j.trre.2024.100873_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.trim.2022.101677","article-title":"Risk factors for cytomegalovirus infection and disease after kidney transplantation: a meta-analysis","volume":"74","author":"Tang","year":"2022","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2024.100873_bb0105","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/infdis\/jit064","article-title":"Cytomegalovirus exposure and cardiovascular disease in kidney transplant recipients","volume":"207","author":"Courivaud","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.trre.2024.100873_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/jama.2023.9106","article-title":"Letermovir vs Valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial","volume":"330","author":"Limaye","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.trre.2024.100873_bb0120","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.kint.2019.01.041","article-title":"An open-label, randomized trial indicates that everolimus with tacrolimus or cyclosporine is comparable to standard immunosuppression in de novo kidney transplant patients","volume":"96","author":"Sommerer","year":"2019","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2024.100873_bb0125","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1111\/ajt.13327","article-title":"Reduced incidence of cytomegalovirus infection in kidney transplant recipients receiving Everolimus and reduced tacrolimus doses","volume":"15","author":"Tedesco-Silva","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100873_bb0130","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/1348-0421.12794","article-title":"Effect of mTOR inhibitors during CMV disease in kidney transplant recipients: results of a pilot retrospective study","volume":"64","author":"Kaminski","year":"2020","journal-title":"Microbiol Immunol"},{"key":"10.1016\/j.trre.2024.100873_bb0135","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.cmi.2023.03.020","article-title":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","volume":"29","author":"Razonable","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.trre.2024.100873_bb0140","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciy706","article-title":"Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, doseranging, double-blind, phase 2 study","volume":"68","author":"Papanicolaou","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.trre.2024.100873_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcv.2006.07.010","article-title":"Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet","volume":"37","author":"Drew","year":"2006","journal-title":"J Clin Virol"},{"key":"10.1016\/j.trre.2024.100873_bb0150","article-title":"Maribavir: first approval","volume":"82","author":"Kang","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.trre.2024.100873_bb0155","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofae335","article-title":"Real-world experience with maribavir for treatment of cytomegalovirus infection in high-risk solid organ transplant recipients","volume":"11","author":"Ni","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.trre.2024.100873_bb0160","article-title":"Kidney Disease: improving global outcomes transplant Work, G. Special issue: KDIGO clinical practice guideline for the care of kidney transplant recipients","volume":"9","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2024.100873_bb0165","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1097\/TP.0000000000002191","article-title":"The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation","volume":"102","author":"Kotton","year":"2018","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2024.100873_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.trre.2020.100587","article-title":"Antiviral treatment approaches for cytomegalovirus prevention in kidney transplant recipients: a systematic review of randomized controlled trials","volume":"35","author":"Raval","year":"2021","journal-title":"Transplant Rev"},{"key":"10.1016\/j.trre.2024.100873_bb0175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3390\/antibiotics10010077","article-title":"Valganciclovir-ganciclovir use and systematic therapeutic drug monitoring. An invitation to antiviral stewardship","volume":"10","author":"Galar","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.trre.2024.100873_bb0180","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13864","article-title":"Cytomegalovirus antiviral stewardship in solid organ transplant recipients: a new gold standard","volume":"24","author":"Jorgenson","year":"2022","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.trre.2024.100873_bb0185","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1097\/QCO.0000000000000963","article-title":"The next frontier: cytomegalovirus antiviral stewardship programs in solid organ transplant","volume":"36","author":"Kleiboeker","year":"2023","journal-title":"Curr Opin Infect Dis"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000569?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X24000569?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,23]],"date-time":"2025-01-23T03:59:17Z","timestamp":1737604757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X24000569"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0955470X24000569"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2024.100873","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maribavir treatment for resistant cytomegalovirus disseminated disease in kidney transplant recipients: A case-based scoping review of real life data in literature","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2024.100873","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"100873"}}